Royalty Pharma
RPRX
$0.17 (0.59%)
1D
1W
3M
1Y
5Y
ALL
Royalty Pharma plc is engaged in investing in late stage biopharmaceutical products. The Company invests in academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. The Company’s portfolio of pharmaceutical investment includes investments in commercial products and development-stage product candidates. Its portfolio investments include AbbVie and J&J’s Imbruvica, Astellas and Pfizer’s Xtandi, Biogen’s Tysabri, Gilead’s HIV franchise, Merck’s Januvia, Novartis’ Promacta, Vertex’s Kalydeco, Orkambi, Symdeko, Trikafta and OXLUMO.
Open
Prior close
Today's high
Today's low
52 Week high
52 Week low
GlobeNewsWire • 1 day ago • RPRX
Royalty Pharma Appoints Molly Sawaya as Executive Vice President, Head of Human CapitalZacks Investment Research • 6 days ago • RPRX
These 2 Finance Stocks Could Beat Earnings: Why They Should Be on Your RadarGlobeNewsWire • 6 days ago • RPRX
Royalty Pharma to Announce Second Quarter 2024 Financial Results on August 8, 2024GlobeNewsWire • 8 days ago • RPRX
Royalty Pharma Declares Third Quarter 2024 DividendZacks Investment Research • 8 days ago • RPRX
Royalty Pharma (RPRX) Recently Broke Out Above the 50-Day Moving AverageCharts and pricing are provided for informational purposes only. The current market data is delayed up to 15 minutes. The accuracy of any market data displayed is not guaranteed.